Eli Lilly to pay $3.2 billion in cash to buy this biotech with an IBD treatment
Morphic’s stock rocketed Monday, after the biopharmaceutical company announced an agreement to be acquired by Eli Lilly in a cash deal valued at about $3.2 billion.
Morphic’s stock rocketed Monday, after the biopharmaceutical company announced an agreement to be acquired by Eli Lilly in a cash deal valued at about $3.2 billion.
